
PB 124 of 2025
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2025 (No. 10)
National Health Act 1953
I, REBECCA RICHARDSON, Assistant Secretary, PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under subsection 98C(1) of the National Health Act 1953.
Dated 29 October 2025
REBECCA RICHARDSON
Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Contents
1. Name...............................................1
2. Commencement.........................................1
3. Authority.............................................1
4. Schedules............................................1
Schedule 1—Amendments............................................2
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019) 2
Commencement information |
| |
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 November 2025 | 1 November 2025 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
insert:
Methylphenidate | Capsule containing methylphenidate hydrochloride 10 mg (modified release) (Switzerland) (S19A) |
insert:
Methylphenidate | Capsule containing methylphenidate hydrochloride 20 mg (modified release) (Switzerland) (s19A) |
insert:
Methylphenidate | Capsule containing methylphenidate hydrochloride 30 mg (modified release) Ritalin LA (Switzerland) (s19A) |
Methylphenidate | Capsule containing methylphenidate hydrochloride 30 mg (modified release) (Switzerland) (s19A) |
insert:
Methylphenidate | Capsule containing methylphenidate hydrochloride 40 mg (modified release) (Switzerland) (s19A) |
[5] Schedule 4, omit entry for Betaxolol
[6] Schedule 4, entries for Estradiol with norethisterone
(a) omit:
Estradiol with norethisterone | Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 (S19A) |
(b) omit:
Estradiol with norethisterone | Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 (S19A) |